Fractyl Health, headquartered in Burlington, Massachusetts, focuses on treating metabolic diseases like type 2 diabetes and obesity with its Revita DMR System and Rejuva gene therapy. The company went public on February 2, 2024, and employs 102 full-time staff.
Fractyl Health (GUTS) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Fractyl Health's actual EPS was -$0.52, missing the estimate of -$0.44 per share, resulting in a -17.20% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
